STZ
42
2
BMY
40
-5
CMA
42
3
DOV
48
2
MDLZ
28
2
O
26
16
TMO
52
8
ABT
54
4
AMG
33
-11
IPG
43
3
WMB
58
3
CAT
47
3
ES
12
3
AFL
34
6
NRG
32
5
XYL
29
4
DOW
47
4
ECL
54
5
SPG
45
2
JNPR
59
3
STZ
42
2
BMY
40
-5
CMA
42
3
DOV
48
2
MDLZ
28
2
O
26
16
TMO
52
8
ABT
54
4
AMG
33
-11
IPG
43
3
WMB
58
3
CAT
47
3
ES
12
3
AFL
34
6
NRG
32
5
XYL
29
4
DOW
47
4
ECL
54
5
SPG
45
2
JNPR
59
3
Financhill
Back

Altamira Therapeutics 10K Form

Sell
19

CYTOF
Altamira Therapeutics

Last Price:
$0.10
Seasonality Move:
-17.35%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CYTOF News And Ratings

See the #1 stock for the next 7 days that we like better than CYTOF

CYTOF Financial Statistics

Sales & Book Value

Annual Sales: $188.4K
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $0.00
Price / Book: 0.07

Profitability

Net Income (TTM): $0
Gross Margin: $-80.6K
Return on Equity: 0%
Return on Assets: 0%

Altamira Therapeutics Earnings Forecast

Key Altamira Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for CYTOF is -42.77%.
  • The Selling, General & Administrative Expenses for CYTOF have been equal to 113.76% of Gross Profit Margin.
  • The Research & Development expenses have been 900.93% of Revenue.
  • The Interest Expense is -17.10% of Operating Income.
  • The Net Earning history of CYTOF is -1,124.77% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 8 years.

Altamira Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CYTOF
Website: altamiratherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYTOF Technical Analysis vs Fundamental Analysis

Sell
19
Altamira Therapeutics (CYTOF) is a Sell

Is Altamira Therapeutics a Buy or a Sell?